ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, June 28th, BidAskClub reports.
Several other analysts also recently weighed in on the stock. TheStreet raised shares of TerraForm Power from a “c” rating to a “b-” rating in a research note on Tuesday, March 19th. Zacks Investment Research raised shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. Canaccord Genuity downgraded shares of Magellan Aerospace from a “buy” rating to a “hold” rating and decreased their price target for the company from C$21.00 to C$20.00 in a research note on Monday, May 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $27.00 price objective on shares of Spero Therapeutics in a research note on Thursday, May 9th. Finally, ValuEngine raised shares of Xylem from a “hold” rating to a “buy” rating in a research note on Friday, June 21st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. ANI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $88.00.
ANI Pharmaceuticals stock traded down $0.25 during trading on Friday, reaching $80.75. The company had a trading volume of 77,965 shares, compared to its average volume of 153,259. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The business’s 50-day moving average is $76.97. The stock has a market capitalization of $972.71 million, a price-to-earnings ratio of 17.52 and a beta of 2.25. ANI Pharmaceuticals has a 52 week low of $36.92 and a 52 week high of $84.10.
In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 30,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $70.07, for a total value of $2,102,100.00. Following the sale, the insider now directly owns 222,994 shares of the company’s stock, valued at $15,625,189.58. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David Nash purchased 1,445 shares of the stock in a transaction on Friday, May 24th. The stock was acquired at an average cost of $68.76 per share, for a total transaction of $99,358.20. Following the completion of the acquisition, the director now owns 5,236 shares of the company’s stock, valued at approximately $360,027.36. The disclosure for this purchase can be found here. Insiders have sold 50,911 shares of company stock worth $3,585,114 over the last three months. Corporate insiders own 24.70% of the company’s stock.
A number of large investors have recently bought and sold shares of ANIP. Financial Gravity Wealth Inc. purchased a new stake in ANI Pharmaceuticals in the first quarter valued at $54,000. Quantamental Technologies LLC raised its position in shares of ANI Pharmaceuticals by 169.4% in the first quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock worth $61,000 after acquiring an additional 542 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $115,000. BNP Paribas Arbitrage SA raised its position in shares of ANI Pharmaceuticals by 55,466.7% in the first quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 1,664 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of ANI Pharmaceuticals by 324.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,872 shares of the specialty pharmaceutical company’s stock worth $129,000 after acquiring an additional 2,195 shares during the period. 63.95% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Story: What does a dividend yield signify to investors?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.